Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean?
- PMID: 18596196
- DOI: 10.3322/ca.2008.0008
Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean?
Abstract
While the past decade has seen the development of multiple new interventions to diagnose and treat cancer, as well as to improve the quality of life for cancer patients, many of these interventions have substantial costs. This has resulted in increased scrutiny of the costs of care for cancer, as well as the costs relative to the benefits for cancer treatments. It is important for oncologists and other members of the cancer community to consider and understand how economic evaluations of cancer interventions are performed and to be able to use and critique these evaluations. This review discusses the components, main types, and analytic issues of health economic evaluations using studies of cancer interventions as examples. We also highlight limitations of these economic evaluations and discuss why members of the cancer community should care about economic analyses.
Similar articles
-
Managing oncology costs.Am J Manag Care. 2006 Feb;12(1 Suppl):S3-16; quiz S17-9. Am J Manag Care. 2006. PMID: 16478368 Review.
-
[Methodology of economic assessment: example in oncology].Bull Cancer. 2003 Nov;90(11):939-45. Bull Cancer. 2003. PMID: 14706896 French.
-
Do oncologists believe new cancer drugs offer good value?Oncologist. 2006 Feb;11(2):90-5. doi: 10.1634/theoncologist.11-2-90. Oncologist. 2006. PMID: 16476830
-
Addressing the American health-care cost crisis: role of the oncology community.J Natl Cancer Inst. 2013 Dec 4;105(23):1777-81. doi: 10.1093/jnci/djt293. Epub 2013 Nov 13. J Natl Cancer Inst. 2013. PMID: 24226096
-
Integrating economic analysis into cancer clinical trials: the National Cancer Institute-American Society of Clinical Oncology Economics Workbook.J Natl Cancer Inst Monogr. 1998;(24):1-28. J Natl Cancer Inst Monogr. 1998. PMID: 9704318 Review. No abstract available.
Cited by
-
Modeling the cost-effectiveness of strategies for treating esophageal adenocarcinoma and high-grade dysplasia.J Gastrointest Surg. 2012 Aug;16(8):1451-61. doi: 10.1007/s11605-012-1911-9. Epub 2012 May 30. J Gastrointest Surg. 2012. PMID: 22644445
-
Cost and effectiveness of video-assisted thoracoscopic surgery for clinical stage I non-small cell lung cancer: a population-based analysis.J Thorac Dis. 2014 Dec;6(12):1690-6. doi: 10.3978/j.issn.2072-1439.2014.10.27. J Thorac Dis. 2014. PMID: 25589961 Free PMC article.
-
Validation of the predictive accuracy of health-state utility values based on the Lloyd model for metastatic or recurrent breast cancer in Japan.BMJ Open. 2021 Dec 1;11(12):e046273. doi: 10.1136/bmjopen-2020-046273. BMJ Open. 2021. PMID: 34853098 Free PMC article.
-
Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study.Pharmacoeconomics. 2018 Feb;36(2):215-223. doi: 10.1007/s40273-017-0580-7. Pharmacoeconomics. 2018. PMID: 29043567 Free PMC article. Clinical Trial.
-
Cost-effectiveness of neoadjuvant concurrent chemoradiotherapy versus esophagectomy for locally advanced esophageal squamous cell carcinoma: A population-based matched case-control study.Thorac Cancer. 2016 Apr 26;7(3):288-95. doi: 10.1111/1759-7714.12326. Epub 2015 Dec 23. Thorac Cancer. 2016. PMID: 27148413 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous